Matches in DBpedia 2016-04 for { ?s ?p "The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s Disease. Specifically the collaboration aims to target protein kinases and the ubiquitylation system in the development of these therapies. It is one of the largest ever collaborations between the commercial pharmaceutical industry and any academic research institute."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Division_of_Signal_Transduction_Therapy abstract "The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s Disease. Specifically the collaboration aims to target protein kinases and the ubiquitylation system in the development of these therapies. It is one of the largest ever collaborations between the commercial pharmaceutical industry and any academic research institute.".
- Q5284564 abstract "The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s Disease. Specifically the collaboration aims to target protein kinases and the ubiquitylation system in the development of these therapies. It is one of the largest ever collaborations between the commercial pharmaceutical industry and any academic research institute.".